A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

By J. Bathon, Richard W. Martin, R. Fleischmann, J. Tesser, M. Schiff, E. Keystone, M. Genovese, M. Wasko, L. Moreland, A. Weaver and 2 more. New England Journal of Medicine, 2000

1,872 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/629e46a2e98b6515a3dc625a45069d80a7035268

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. J. Smolen
2. D. Tracey
3. C. Brinckerhoff
4. Lars Klareskog
5. J. Salfeld
6. P. Tak
7. E. Sasso
8. S. Rose‐John

Citations in the corpus

• Bacterial metabolism and health‐related effects of galacto‐oligosaccharides and other prebiotics (2007, background): “…chimeric monoclonal antibodies in the treatment of rheumatoid arthritis and IBD to reduce levels of TNF-a and other pro-inflammatory cytokines, and disrupt inflammatory networks (Smolen et al. 1999; Bathon et al. 2000; Travis et al. 2006), is also indicative of a linkage between these conditions.”
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. (2006, background): “Unlike the Early Rheumatoid Arthritis (etanercept monotherapy) (ERA) (44) and Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (32) studies, the PREMIER study included 3 treatment arms (combination therapy, anti-TNF therapy alone, and ”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, neutral): “(level 1b, grade A). At the time of the SLR, the only biological agents licensed in Europe for treating patients with RA with active disease despite synthetic DMARD treatment were the TNF inhibitors and tocilizumab; rituximab and abatacept are currently licensed only for use after failure of TNF inh”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “R., et al. (2005). Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.”
• Binding and functional comparisons of two types of tumor necrosis factor antagonists. (2002, background): “, 2000) and etanercept (Enbrel; Immunex, Seattle, WA) (Moreland et al., 1997; Weinblatt et al., 1999; Bathon et al., 2000), later confirmed that inhibiting TNF activity conferred pronounced clinical benefits.”
• Systemic effects of chronic obstructive pulmonary disease (2003, background): “These antibodies have been effective in the treatment of other chronic inflammatory diseases, such as rheumatoid arthritis, in which TNF-a plays a key pathogenic role [140–145].”
• Matrix metalloproteinases: role in arthritis. (2006, background): “Therapy with this drug reduced pain and inflammation as well as radiographic damage in RA, implying that MMP-mediated bone destruction was reduced (140).”
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. (2004, background): “Adverse events occurring at a rate of 10%† URI 60 (21) 94 (25) 106 (28) Nausea 53 (18) 73 (20) 65 (17) Headache 31 (11) 43 (12) 42 (11) Sinusitis 24 (8) 46 (12) 38 (10) Pharyngitis 17 (6) 33 (9) 40 (11) Patients with 1 serious adverse event‡ 32 (11) 52 (14) 51 (14)”
• Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. (2002, methodology): “The study design and results of the double-blind portion of this trial have been previously reported (1).”
• Guidelines for the management of rheumatoid arthritis: 2002 Update. (2002, positive): “In the trial of patients with early RA (96), the symptoms and signs of RA improved more rapidly with etanercept treatment than with MTX treatment over the first 6 months, with comparable efficacy of the two agents at 12 months.”